Objective: To evaluate the effects and safety of monthly intraovarian injection of autologous platelet-rich plasma (PRP) for three consecutive cycles prior to in vitro fertilization and embryo transfer (IVF–ET) on ovarian reserve markers in women with poor ovarian response (POR) as per Bologna criteria. Materials and methods: This is a prospective cohort study of 66 women diagnosed as poor ovarian responders as per the Bologna criteria were recruited in the study from 1 January 2018 to 31 December 2020. Platelet-rich plasma was prepared from peripheral blood and PRP activation was achieved with 0.1 cc of 10% calcium gluconate. Platelet-rich plasma injection into ovarian stroma was performed transvaginally, under ultrasound guidance, into both ovaries using a 35 cm single lumen 17G needle between D7 and D12 of the menstrual cycle in three consecutive cycles. Antral follicle count (AFC) and anti-müllerian hormone (AMH) were measured from the second to fourth day of menstruation before the first PRP treatment and immediately following last PRP administration. Ovarian stimulation and in vitro fertilization (IVF) embryo transfer were performed immediately following the last PRP administration. The primary outcomes were the change in AFC post-PRP treatment. Secondary outcomes were increased in serum AMH, the total number of oocytes retrieved and clinical pregnancy rates. Results: Sixty-six women were included. After three cycles of ovarian PRP administration, there was a significant increase in AFC mean (SD) 4.85 (4.65) compared to pre-treatment AFC. There was a statistically significant difference between pre- and post-treatment AFC (5.21 vs 10.06, p < 0.0001). Improved post-treatment AFC was not limited to younger patients; when stratified by age, significant AFC improvements were seen in patients of age less than 35 years as well as more than 35 years (p < 0.0001). Furthermore, the significant increase was seen in mean serum AMH level following PRP treatment (1.18 vs 0.93, p < 0.0001). The improvement in serum AMH levels were seen across all age patients (<35 years vs ≥35 years). The mean (SD) number of oocytes retrieved were 7.49 (4.45) and pregnancy rate was 25%. The PRP treatment was well tolerated. Conclusion: Intraovarian PRP injections are effective to improve AFC, AMH prior to antiretroviral therapy (ART) in poor ovarian responders, and results in reasonable number of oocytes retrieved following ovarian stimulation.